Abata Therapeutics is a technology company.
Abata Therapeutics is a technology company.
Abata Therapeutics has raised $95.0M across 1 funding round.
Key people at Abata Therapeutics.
Abata Therapeutics has raised $95.0M in total across 1 funding round.
Abata Therapeutics is a biotechnology company developing targeted, autologous regulatory T cell (Treg) therapies for severe autoimmune and inflammatory diseases, such as progressive multiple sclerosis and type 1 diabetes, where current treatments are inadequate.[1][2][3] Its lead candidate, ABA-101, targets myelin basic protein (MBP) modulators for multiple sclerosis in Phase 1 trials, while ABA-201 addresses protein phosphatase inhibitor (PPI) modulators for type 1 diabetes at the IND stage, serving patients in healthcare and biotech sectors with therapies aimed at halting immune destruction, restoring homeostasis, and promoting tissue repair.[1][3] The small organization (under 50 employees) demonstrates growth momentum through clinical advancements, a strong leadership team, and recognition for its workplace culture.[2][5]
Founded in 2020 and headquartered in Watertown, Massachusetts, Abata Therapeutics emerged from advances in Treg biology to address unmet needs in autoimmune diseases.[1][2] Key leaders include CEO and President Samantha Singer, Chief Scientific Officer Ellen Cahir-McFarland, Chief Medical Officer Leonard Dragone, and a board featuring experts like Abbie Celniker, Mitch Finer, and Nagesh Mahanthappa, reflecting deep biotech pedigrees in cell therapy and immunology.[5] Early traction built on translating Treg research into pipeline assets like ABA-101, with a pivotal moment in September 2024 when its discovery-stage myositis program advanced, alongside Phase 1 initiation for multiple sclerosis.[3]
Abata rides the wave of cell therapy innovation in autoimmune diseases, where Tregs address root immune dysregulation amid a booming pipeline of MS therapies like tolebrutinib and fenebrutinib, yet few offer reparative potential.[1][3] Timing aligns with surging demand for precision immunology, fueled by market forces like aging populations driving nervous and immune system disease prevalence, plus regulatory tailwinds for INDs and Phase 1 trials.[3] It influences the ecosystem by advancing Treg platforms, potentially setting benchmarks for tissue-targeted autologous therapies and complementing digital health/biotech peers like Benchling and Cityblock Health in integrated care models.[5]
Abata's near-term catalysts include ABA-101 Phase 1 data readouts and ABA-201 IND clearance, positioning it for partnerships or Series B funding in a hot cell therapy market.[3][5] Trends like AI-driven drug discovery (echoed in peers like insitro) and expanded autoimmune indications will shape its path, potentially evolving its influence toward multi-disease Treg dominance if clinical momentum sustains.[1][5] This Treg pioneer could redefine autoimmune treatment, returning to its core mission of transformational medicines where options fall short.[2]
Key people at Abata Therapeutics.
Abata Therapeutics has raised $95.0M in total across 1 funding round.
Abata Therapeutics's investors include Third Rock Ventures.
Abata Therapeutics has raised $95.0M across 1 funding round. Most recently, it raised $95.0M Series A in June 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2021 | $95.0M Series A | Third Rock Ventures |
